Yazar "Aladag, H." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Galectin-1 as a potential diagnostic biomarker in polycystic ovary syndrome
    (Verduci Publisher, 2023) Aladag, H.; Kiran, T. R.; Inceoglu, F.; Yildirim, E.; Yaprak, B.; Karabulut, A. B.; Aladag, M.
    OBJECTIVE: This study was aimed at comparing the routine laboratory pa-rameters and Galectin-1 levels of control and polycystic ovarian syndrome patients.PATIENTS AND METHODS: 88 patients di-agnosed with polycystic ovary syndrome and 88 healthy controls were considered for the study. Age groups of the patients ranged from 18 to 40. Serum TSH, Beta HCG, glucose, insulin, HO-MA-IR, Hb1A1c, triglyceride, total cholesterol, LDL FSH, LH, E2, prolactin, testosterone, SHBG, DHESO4, HDL, Gal-1 levels were analyzed for each subject.RESULTS: FSH, LH, LH/FSH, E2, prolactin, testosterone, SHBG, DHESO4, HDL and Gal -1 values of the subjects included in the study were statistically significantly different between the groups (p<0.05). Gal-1 and DHESO4 showed a strong positive connection (p=0.05). The sen-sitivity of Gal-1 level in PCOS patients was cal-culated as 0.997 and specificity as 0.716.CONCLUSIONS: High levels of Gal-1 in PCOS patients suggest that it increases due to overex-pression in response to inflammation.
  • Küçük Resim Yok
    Öğe
    Is the use of Tenofovir Dipivoxil fumarate effective and safe in preventing vertical transmission in pregnant women with chronic HBV with high viral load?
    (Verduci Publisher, 2023) Aladag, H.; Aladag, M.
    OBJECTIVE: In our country, transmission from mother to baby is the most common form of transmission of viral hepatitis B. A high viral load in the mother and HBeAg positivity pose the greatest risk of transmission from mother to baby. The best way to pre-vent this is to try to eliminate the viral load in the mother by using a strong antiviral such as prenatal TDF in mothers with a high viral load during pregnancy. This study aimed to evaluate the efficacy and safety of TDF in pregnant women with high viral load.PATIENTS AND METHODS: Seventy patients with hepatitis B e-antigen positive and negative were included in the retrospective study conducted in our clinic. In 35 cases, pregnant women with HBeAg (+) positive chronic HBV and HBV-DNA levels of 107 copies/mL were be-tween 18 and 27 weeks of pregnancy. The preg-nant women took 300 mg of TDF per day. There were 35 untreated HBeAg-negative, chronic HBV patients in the control group. Babies born to HBeAg-positive and HBeAg-negative mothers are given an initial dose of 200 IU of hepatitis B immune globulin (HBIG) and 20 g of recombi-nant hepatitis B vaccine in the first 12 hours af-ter birth, followed by 4, 8, and 24 weeks. HBsAg and HBV-DNA findings were examined in new-born serum 28 weeks after birth.RESULTS: Postpartum 28 weeks, none of the babies born to HBeAg-positive mothers treated with TDF had HBsAg positivity, while 3.5% of babies born to HBeAg-negative mothers and not treated with TDF had HBsAg positivity and immunoprophylaxis failure. There was no statistically significant difference between the treatment and control groups regarding maternal height, weight, gestational age, or congenital malformations (p<0.05). There was no signifi-cant difference between the side effects seen in mothers. In the examination performed at the 28th week postpartum, a statistically signifi-cant decrease in HBV-DNA levels was observed in mothers who received TDF treatment com-pared to those who did not (88.5%) (p<0.05). In 31 of the 35 patients receiving TDF treatment, ALT was reported to be normalized in 25 of the 35 patients who did not receive TDF treatment (p<0.05).CONCLUSIONS: It has been observed that the use of TDF, which has a strong efficacy and high barrier, in the second and/or third trimester of pregnancy reduces transmission rates without causing side effects in both the mother and the newborn, thereby preventing vertical transmission of viral hepatitis B from the mother to child.